Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/03/2009US7611730 Containing racemate of tramadol in slow-release form and (+)enantiomer of tramadol in immediate-release form; analgesic efficacy results from interplay of enantiomers by mechanism which includes non-opioid and opiod components
11/03/2009US7611729 Dosage forms having prolonged active ingredient release
11/03/2009US7611722 Reduced contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug.
11/03/2009US7611716 Method of processing seaweed
11/03/2009US7611694 Scopine 2,2-diphenylpropionate-metho halides and other salts: propellant-free solution with ethanol and water and an acid; optimum nebulization; storage stability; nebulizer
11/03/2009US7611693 Mechanism-based targeted pancreatic beta cell imaging and therapy
11/03/2009CA2565660C Ortho substituted aryl or heteroaryl amide compounds
11/03/2009CA2514224C Liquid pharmaceutical formulations of palonosetron
11/03/2009CA2474510C Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
11/03/2009CA2457982C Use of nefiracetam for treating neurodegeneration
11/03/2009CA2449729C Prodrugs of gaba analogs, compositions and uses thereof
11/03/2009CA2448035C New pharmaceutical composition
11/03/2009CA2447924C Olopatadine formulations for topical administration
11/03/2009CA2443724C Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
11/03/2009CA2442423C Therapeutic drug for psychoneurotic disorders
11/03/2009CA2435524C Use of hederagenin 3-o-.alpha.-l-rhamnopyranosyl((1->2)-[.beta.-d-glucopyranosyl(1->4)]-.alpha.-l-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors
11/03/2009CA2424579C Ultraviolet-screening patch
11/03/2009CA2421990C .beta.-thioamino acids
11/03/2009CA2420585C Amides of r-2-(aminoaryl)-propionic acids for use in the prevention of leucocyte activation
11/03/2009CA2420579C Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine
11/03/2009CA2418008C Antifungal ketoconazole composition for topical use
11/03/2009CA2415476C Matrix controlled transdermal system for stabile derivatives of ace inhibitors
11/03/2009CA2410037C 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
11/03/2009CA2409926C Praziquantel compounds for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/03/2009CA2407421C Activators of peroxisome proliferator-activated receptors
11/03/2009CA2404210C Pharmaceutical gel composition
11/03/2009CA2402222C Sustained release ranolazine formulations
11/03/2009CA2394987C Method for preparing ortho silicic acid, ortho silicic acid as obtained, and its use
11/03/2009CA2391343C Skin care composition
11/03/2009CA2385477C Pca3 messenger rna species in benign and malignant prostate tissues
11/03/2009CA2383327C Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
11/03/2009CA2372668C Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
11/03/2009CA2368834C Bicyclic heteroaromatic compounds useful as lh agonists
11/03/2009CA2360767C Tricyclic benzodiazepines as vasopressin receptor antagonists
11/03/2009CA2356896C Method for high yield extraction of paclitaxel from paclitaxel-containing material
11/03/2009CA2353133C Treatment of disorders secondary to organic impairments
11/03/2009CA2324283C Pharmaceutical composition containing a statin and aspirin
11/03/2009CA2320991C Calorically dense nutritional composition
11/03/2009CA2316356C Benzoxazine compounds for enhancing synaptic response
11/03/2009CA2314043C Liquid mixture consisting of diesel gas oils and oxygenated compounds
11/03/2009CA2213663C Polyalkylene block copolymers as surface modifiers for nanoparticles
11/03/2009CA2205379C Yeast-based delivery vehicles
11/03/2009CA2187626C Aav-mediated delivery of dna to cells of the nervous system
11/03/2009CA2174338C Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
10/2009
10/30/2009CA2699190A1 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
10/30/2009CA2638573A1 Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
10/29/2009WO2009132343A1 Nanoemulsions for treating onchomycosis
10/29/2009WO2009132342A1 Nanoemulsions for treating fungal, yeast and mold infections
10/29/2009WO2009132320A2 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
10/29/2009WO2009132313A2 Morphinan derivatives of organic and inorganic acids
10/29/2009WO2009132307A1 Small-molecule inhibitors of the androgen receptor
10/29/2009WO2009132265A2 Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
10/29/2009WO2009132253A1 Use of epothelone d in treating tau-associated diseases including alzheimer's disease
10/29/2009WO2009132238A2 Ido inhibitors
10/29/2009WO2009132234A2 Medical devices, polymers, compositions, and methods for delivering a haloacetate
10/29/2009WO2009132228A1 Chitosan-containing protective composition
10/29/2009WO2009132227A1 Protective gel based on chitosan and oxidized polysaccharide
10/29/2009WO2009132226A1 Thiolated chitosan gel
10/29/2009WO2009132208A1 Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
10/29/2009WO2009132172A1 Isoxazoline compounds and their use to suppress inflammation or treat inflammatory disease
10/29/2009WO2009132149A2 Treatment of conditions related to cecal ligation shock
10/29/2009WO2009132136A1 Carboxamide compounds for the treatment of metabolic disorders
10/29/2009WO2009132135A1 1' -substituted carba-nucleoside analogs for antiviral treatment
10/29/2009WO2009132123A1 Carba-nucleoside analogs for antiviral treatment
10/29/2009WO2009132119A2 Substituted oxazolidinones
10/29/2009WO2009132101A1 Methods of treating fungal infections
10/29/2009WO2009132097A1 Substituted gamma lactams as therapeutic agents
10/29/2009WO2009132093A2 Substituted arylcyclopentenes as therapeutic agents
10/29/2009WO2009132088A1 Substituted gamma lactams as therapeutic agents
10/29/2009WO2009132087A1 Thiophene derivatives useful as ocular hypotensive agents
10/29/2009WO2009132085A1 Substituted arylcyclopentenes as prostaglandin ep2 agonists
10/29/2009WO2009132051A1 Compounds, compositions and methods for making the same
10/29/2009WO2009132048A2 Treating eosinophilic esophagitis
10/29/2009WO2009132020A2 Selective high-affinity polydentate ligands and methods of making such
10/29/2009WO2009132000A1 Quinoline or isoquinoline substituted p2x7 antagonists
10/29/2009WO2009131975A1 Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
10/29/2009WO2009131974A1 Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
10/29/2009WO2009131973A1 Quinolone derivatives useful as antibacterial agents
10/29/2009WO2009131958A2 Compounds, compositions and methods comprising triazine derivatives
10/29/2009WO2009131957A2 Compounds, compositions and methods comprising oxadiazole derivatives
10/29/2009WO2009131954A2 Compounds, compositions and methods comprising oxadiazole derivatives
10/29/2009WO2009131952A1 Compounds, compositions and methods comprising thiazole derivatives
10/29/2009WO2009131951A2 Compounds, compositions and methods comprising isoxazole derivatives
10/29/2009WO2009131947A2 Compounds, compositions and methods comprising pyridazine derivatives
10/29/2009WO2009131940A1 Limk2 inhibitors, compositions comprising them, and methods of their use
10/29/2009WO2009131926A1 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
10/29/2009WO2009131906A1 Cyclobutyl sulfones as notch sparing gamma secretase inhibitors
10/29/2009WO2009131850A2 Pai-1 expression and activity inhibitors for the treatment of ocular disorders
10/29/2009WO2009131815A1 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
10/29/2009WO2009131814A2 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
10/29/2009WO2009131794A1 Opioid-ketamine and norketamine codrug combinations for pain management
10/29/2009WO2009131704A2 Nanostructures suitable for sequestering cholesterol and other molecules
10/29/2009WO2009131696A1 Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
10/29/2009WO2009131687A2 Inhibitors of protein kinases
10/29/2009WO2009131654A2 Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
10/29/2009WO2009131553A2 Methods of altering bone growth by administration of sost or wise antagonist or agonist
10/29/2009WO2009131537A1 New therapy of treatment of the irritable bowel syndrome.
10/29/2009WO2009131434A1 Extracellular scaffolds comprising blends of polyvinyl alcohol and carboxymethyl chitosan
10/29/2009WO2009131384A2 Pharmaceutical composition for preventing and treating malaria, containing compounds that inhibit plasmepsin ii activity, and method of treating malaria using the same
10/29/2009WO2009131291A1 (d)-allose inducing programmed cell death in hormone refractory prostate cancer lines
1 ... 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 ... 7860